636 related articles for article (PubMed ID: 9456249)
1. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
[TBL] [Abstract][Full Text] [Related]
2. Antibody-secreting cells specific for simian immunodeficiency virus antigens in lymphoid and mucosal tissues of immunized macaques.
Bergmeier LA; Mitchell EA; Hall G; Cranage MP; Cook N; Dennis M; Lehner T
AIDS; 1998 Jul; 12(10):1139-47. PubMed ID: 9677162
[TBL] [Abstract][Full Text] [Related]
3. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques.
Lehner T; Wang Y; Cranage M; Bergmeier LA; Mitchell E; Tao L; Hall G; Dennis M; Cook N; Jones I; Doyle C
Dev Biol Stand; 1998; 92():225-35. PubMed ID: 9554279
[TBL] [Abstract][Full Text] [Related]
4. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
5. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.
Miller CJ; McChesney MB; Lü X; Dailey PJ; Chutkowski C; Lu D; Brosio P; Roberts B; Lu Y
J Virol; 1997 Mar; 71(3):1911-21. PubMed ID: 9032322
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.
Buge SL; Murty L; Arora K; Kalyanaraman VS; Markham PD; Richardson ES; Aldrich K; Patterson LJ; Miller CJ; Cheng SM; Robert-Guroff M
J Virol; 1999 Sep; 73(9):7430-40. PubMed ID: 10438833
[TBL] [Abstract][Full Text] [Related]
7. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
8. Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques.
Kawabata S; Miller CJ; Lehner T; Fujihashi K; Kubota M; McGhee JR; Imaoka K; Hiroi T; Kiyono H
J Infect Dis; 1998 Jan; 177(1):26-33. PubMed ID: 9419166
[TBL] [Abstract][Full Text] [Related]
9. A Mucosal Adenovirus Prime/Systemic Envelope Boost Vaccine Regimen Elicits Responses in Cervicovaginal and Alveolar Macrophages of Rhesus Macaques Associated With Delayed SIV Acquisition and B Cell Help.
Hunegnaw R; Helmold Hait S; Enyindah-Asonye G; Rahman MA; Ko EJ; Hogge CJ; Hoang T; Robert-Guroff M
Front Immunol; 2020; 11():571804. PubMed ID: 33117363
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.
Manrique M; Kozlowski PA; Cobo-Molinos A; Wang SW; Wilson RL; Montefiori DC; Carville A; Aldovini A
J Virol; 2013 Apr; 87(8):4738-50. PubMed ID: 23408627
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
13. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
14. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
15. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
Mossman SP; Bex F; Berglund P; Arthos J; O'Neil SP; Riley D; Maul DH; Bruck C; Momin P; Burny A; Fultz PN; Mullins JI; Liljeström P; Hoover EA
J Virol; 1996 Mar; 70(3):1953-60. PubMed ID: 8627721
[TBL] [Abstract][Full Text] [Related]
16. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.
Israel ZR; Edmonson PF; Maul DH; O'Neil SP; Mossman SP; Thiriart C; Fabry L; Van Opstal O; Bruck C; Bex F
J Virol; 1994 Mar; 68(3):1843-53. PubMed ID: 8107246
[TBL] [Abstract][Full Text] [Related]
17. The effect of immunization on chemokines and CCR5 and CXCR4 coreceptor functions in SIV binding and chemotaxis.
Wang Y; Tao L; Mitchell E; Bergmeier L; Doyle C; Lehner T
Vaccine; 1999 Apr; 17(15-16):1826-36. PubMed ID: 10217580
[TBL] [Abstract][Full Text] [Related]
18. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.
Alpert MD; Rahmberg AR; Neidermyer W; Ng SK; Carville A; Camp JV; Wilson RL; Piatak M; Mansfield KG; Li W; Miller CJ; Lifson JD; Kozlowski PA; Evans DT
J Virol; 2010 Oct; 84(20):10748-64. PubMed ID: 20702641
[TBL] [Abstract][Full Text] [Related]
19. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.
Buge SL; Richardson E; Alipanah S; Markham P; Cheng S; Kalyan N; Miller CJ; Lubeck M; Udem S; Eldridge J; Robert-Guroff M
J Virol; 1997 Nov; 71(11):8531-41. PubMed ID: 9343211
[TBL] [Abstract][Full Text] [Related]
20. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
